LL Silver Consulting, LLC, 955 S. Springfield Ave., Unit C403, Springfield, NJ 07081, USA.
Clin Microbiol Rev. 2011 Jan;24(1):71-109. doi: 10.1128/CMR.00030-10.
The discovery of novel small-molecule antibacterial drugs has been stalled for many years. The purpose of this review is to underscore and illustrate those scientific problems unique to the discovery and optimization of novel antibacterial agents that have adversely affected the output of the effort. The major challenges fall into two areas: (i) proper target selection, particularly the necessity of pursuing molecular targets that are not prone to rapid resistance development, and (ii) improvement of chemical libraries to overcome limitations of diversity, especially that which is necessary to overcome barriers to bacterial entry and proclivity to be effluxed, especially in Gram-negative organisms. Failure to address these problems has led to a great deal of misdirected effort.
新型小分子抗菌药物的发现已经停滞多年。本文旨在强调并说明那些在发现和优化新型抗菌药物方面特有的科学问题,这些问题对研究成果产生了不利影响。主要挑战分为两个方面:(i)正确的靶标选择,特别是追求不易产生快速耐药性的分子靶标是必要的,以及(ii)化学文库的改进,以克服多样性的限制,特别是克服细菌进入和易被外排的障碍所必需的多样性限制,特别是在革兰氏阴性菌中。未能解决这些问题导致了大量的错误努力。